<DOC>
	<DOCNO>NCT00637702</DOCNO>
	<brief_summary>This Phase 1 study patient advance solid tumor receive new formulation investigational study drug ARRY-334543 . Patients receive increase dos study drug order achieve high dose possible cause unacceptable side effect . The patient follow see side effect effectiveness study drug , , treat cancer . In addition , effect food new formulation evaluate . Approximately 24 patient Canada enrol study ( Active , recruit ) .</brief_summary>
	<brief_title>A Study ARRY-334543 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Key Histological cytological evidence malignancy . Patients advance solid tumor longer candidate standard therapy , standard therapy available , choose pursue standard therapy . Cardiac ejection fraction â‰¥ 50 % echocardiogram ( ECHO ) multiple gated acquisition ( MUGA ) . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 . Additional criterion exist . Key Uncontrolled brain metastasis ( patient brain metastasis steroid , steroid dose must stable least 30 day ) . Use investigational medication device within 30 day prior first dose study drug . Major surgery within 30 day prior first dose study drug . Radiotherapy chemotherapy within 28 day prior first dose study drug ( include palliative radiotherapy focal site ) . Active , uncontrolled infection require systemic antibiotic therapy serious underlie medical condition would impair ability patient receive protocol treatment . Pregnancy lactation . Known positive serology human immunodeficiency virus ( HIV ) , 'active ' hepatitis B and/or hepatitis C. Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>